Aripiprazole

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

Aripiprazole, which is also sold under the brand names Abilify and Aripiprazol, is an atypical antipsychotic drug and anti-inflammatory drug used for a number of different conditions including:

Theory[edit | edit source]

One hypothesized theory of aripiprazole’s mode of action is that it may work as a biofilm disruptor[2] and affect the gut-brain axis that way.

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Aripiprazole is not approved for use in ME/CFS, and no clinical trials have been conducted with ME/CFS patients. Aripiprazole is approved by the FDA, by the European Medicines Agency (EMA) and UK's Medicines Agency for schizophrenia, manic episodes in bipolar I disorder, and for irritability associated with autistic disorders, and other uses.[3] Aripiprazole is sometimes used as an add-on treatment together with an antidepressant.[4]

Aripiprazole, including the brand name Abilify, is an inexpensive perscription-only drug, available as an oral solution, tablet, disolvable powder, and as a powder for injections.[4][5]

Patient group statements[edit | edit source]

Talks, presentations and videos[edit | edit source]

Notable studies[edit | edit source]

  • 2012, The role of Antipsychotics in the Management of Fibromyalgia[6] - (Abstract)
  • 2018, Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation[7](Full text)
  • 2019, Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans[8]
  • 2021, Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole[9](Full text)
correction

Articles and blogs[edit | edit source]

Blogs[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Aripiprazole". Drugs.com. Retrieved October 4, 2020.
  2. Rajasekharan, Satish Kumar; Lee, Jin-Hyung; Lee, Jintae (October 2019). "Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans". International Journal of Antimicrobial Agents. 54 (4): 518–523. doi:10.1016/j.ijantimicag.2019.05.016. ISSN 1872-7913. PMID 31173863.
  3. "Abilify 5mg tablets". Electronic Medicines Compendium. Retrieved November 3, 2021.
  4. 4.04.1 "Ability medication guide". Food and Drug Administration. Retrieved November 3, 2021.
  5. "Aripiprazole Search Results". Electronic Medicines Compendium. Retrieved November 3, 2021.
  6. Calandre, Elena P.; Rico-Villademoros, Fernando (February 1, 2012). "The Role of Antipsychotics in the Management of Fibromyalgia". CNS Drugs. 26 (2): 135–153. doi:10.2165/11597130-000000000-00000. ISSN 1179-1934.
  7. Omori, Yuki; Kanbayashi, Takashi; Sagawa, Yohei; Imanishi, Aya; Tsutsui, Ko; Takahashi, Yuya; Takeshima, Masahiro; Takaki, Manabu; Nishino, Seiji (May 18, 2018). "Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation". Neuropsychiatric Disease and Treatment. 14: 1281–1286. doi:10.2147/NDT.S158865. ISSN 1176-6328. PMC 5965391. PMID 29849459.
  8. Rajasekharan, Satish Kumar; Lee, Jin-Hyung; Lee, Jintae (October 2019). "Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans". International Journal of Antimicrobial Agents. 54 (4): 518–523. doi:10.1016/j.ijantimicag.2019.05.016. ISSN 1872-7913. PMID 31173863.
  9. Crosby, L.D.; Kalanidhi, S.; Bonilla, A.; Subramanian, A.; Ballon, J. S.; Bonilla, H. (February 3, 2021). "Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole". Journal of Translational Medicine. 19 (1): 50. doi:10.1186/s12967-021-02721-9. ISSN 1479-5876. PMC 7860172. PMID 33536023.
  10. Dafoe, Whitney (May 2021). "Extremely Severe ME/CFS—A Personal Account". Healthcare. 9 (5): 504. doi:10.3390/healthcare9050504.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.